Cargando…
The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
BACKGROUND: Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of death from a bacterial infection. The 4-aminopiperidine (PIP) series has been reported as having anti-bacterial activity against M. tuberculosis. We explored this series for its potential to inhibit aerobic gr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336482/ https://www.ncbi.nlm.nih.gov/pubmed/25881065 http://dx.doi.org/10.1186/s12952-015-0024-x |
_version_ | 1782358475553112064 |
---|---|
author | Chandrasekera, N Susantha Alling, Torey Bailey, Mai Korkegian, Aaron Ahn, James Ovechkina, Yulia Odingo, Joshua Parish, Tanya |
author_facet | Chandrasekera, N Susantha Alling, Torey Bailey, Mai Korkegian, Aaron Ahn, James Ovechkina, Yulia Odingo, Joshua Parish, Tanya |
author_sort | Chandrasekera, N Susantha |
collection | PubMed |
description | BACKGROUND: Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of death from a bacterial infection. The 4-aminopiperidine (PIP) series has been reported as having anti-bacterial activity against M. tuberculosis. We explored this series for its potential to inhibit aerobic growth of M. tuberculosis. We examined substitution at the N-1 position and C-4 position of the piperidine and modifications of the piperidine moiety systematically to delineate structure-activity relationships influencing potency. Compounds were tested for growth-inhibitory activity against virulent M. tuberculosis. A selected set of compounds were also tested for its activity against Staphylococcus aureus. RESULTS: The compound with a norbornenylmethyl substituent at the N-1 position and N-benzyl-N-phenethylamine at the C-4 position of the piperidine (1) was the only active compound with a minimum inhibitory concentration (MIC) of 10 μM against M. tuberculosis. Compounds were not active against S. aureus. CONCLUSIONS: We were unable to derive any other analogs with MIC < 20 μM against M. tuberculosis. Therefore we conclude that the lack of activity is a liability in this series precluding it from further development. |
format | Online Article Text |
id | pubmed-4336482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43364822015-02-22 The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity Chandrasekera, N Susantha Alling, Torey Bailey, Mai Korkegian, Aaron Ahn, James Ovechkina, Yulia Odingo, Joshua Parish, Tanya J Negat Results Biomed Research BACKGROUND: Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of death from a bacterial infection. The 4-aminopiperidine (PIP) series has been reported as having anti-bacterial activity against M. tuberculosis. We explored this series for its potential to inhibit aerobic growth of M. tuberculosis. We examined substitution at the N-1 position and C-4 position of the piperidine and modifications of the piperidine moiety systematically to delineate structure-activity relationships influencing potency. Compounds were tested for growth-inhibitory activity against virulent M. tuberculosis. A selected set of compounds were also tested for its activity against Staphylococcus aureus. RESULTS: The compound with a norbornenylmethyl substituent at the N-1 position and N-benzyl-N-phenethylamine at the C-4 position of the piperidine (1) was the only active compound with a minimum inhibitory concentration (MIC) of 10 μM against M. tuberculosis. Compounds were not active against S. aureus. CONCLUSIONS: We were unable to derive any other analogs with MIC < 20 μM against M. tuberculosis. Therefore we conclude that the lack of activity is a liability in this series precluding it from further development. BioMed Central 2015-02-13 /pmc/articles/PMC4336482/ /pubmed/25881065 http://dx.doi.org/10.1186/s12952-015-0024-x Text en © Chandrasekera et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Chandrasekera, N Susantha Alling, Torey Bailey, Mai Korkegian, Aaron Ahn, James Ovechkina, Yulia Odingo, Joshua Parish, Tanya The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity |
title | The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity |
title_full | The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity |
title_fullStr | The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity |
title_full_unstemmed | The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity |
title_short | The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity |
title_sort | 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336482/ https://www.ncbi.nlm.nih.gov/pubmed/25881065 http://dx.doi.org/10.1186/s12952-015-0024-x |
work_keys_str_mv | AT chandrasekeransusantha the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT allingtorey the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT baileymai the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT korkegianaaron the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT ahnjames the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT ovechkinayulia the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT odingojoshua the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT parishtanya the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT chandrasekeransusantha 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT allingtorey 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT baileymai 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT korkegianaaron 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT ahnjames 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT ovechkinayulia 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT odingojoshua 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity AT parishtanya 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity |